Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA609430
Max Phase: Preclinical
Molecular Formula: C16H11ClFN3O2
Molecular Weight: 295.27
Molecule Type: Small molecule
Associated Items:
ID: ALA609430
Max Phase: Preclinical
Molecular Formula: C16H11ClFN3O2
Molecular Weight: 295.27
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[n+]1c2ccc(F)cc2cc2[n-]c3c([N+](=O)[O-])cccc3c21.Cl
Standard InChI: InChI=1S/C16H10FN3O2.ClH/c1-19-13-6-5-10(17)7-9(13)8-12-16(19)11-3-2-4-14(20(21)22)15(11)18-12;/h2-8H,1H3;1H
Standard InChI Key: LKVQFHVIMGWJGW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 295.27 | Molecular Weight (Monoisotopic): 295.0757 | AlogP: 2.98 | #Rotatable Bonds: 1 |
Polar Surface Area: 61.12 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 6.54 | CX Basic pKa: | CX LogP: -0.94 | CX LogD: -1.58 |
Aromatic Rings: 4 | Heavy Atoms: 22 | QED Weighted: 0.31 | Np Likeness Score: -0.68 |
1. Seville S, Phillips RM, Shnyder SD, Wright CW.. (2007) Synthesis of cryptolepine analogues as potential bioreducible anticancer agents., 15 (19): [PMID:17643990] [10.1016/j.bmc.2007.06.062] |
Source(1):